Method considerations for therapeutic oligonucleotide (ASO) RNA analysis

Oligonucleotide analysis has gained considerable interest over the last few years with the successful introduction of mRNA vaccines and the synthetic short interfering RNA therapeutics.

Synthetic RNA drug products extend the need for new analytics to accurately determine impurities generated during manufacture. The highly charged, linear chain structure already provides analytical challenges. The introduction of sulphur onto an asymmetric phosphate group for stability causes additional chromatography related problems. Amine ion pair and metal adducts create a quantitation problem due to multiple split signals. In-source generated impurities compound this problem.

This webinar will present a successful routine method with optimized HRMS conditions developed for synthetic oligonucleotide impurity analysis which resolves all of these problems. We hope to see you there!

Learning Points:

• Routine method for synthetic oligonucleotide impurity analysis
• How to resolve analytical challenges for ASO RNA analysis

Who should attend?

• Biopharmaceutical Research Scientists
• Analytical Scientists from Biopharma companies working on or interested in oligonucleotide-based therapies
• PhD students and scientists looking to advance knowledge of oligonucleotide analysis

Short notice:

Can't attend the live broadcast? No problem! Register anyway and you will automatically receive the link to the webinar recording.

Presenter: Dr. Ken Cook (European Manager BioPharma Expert Support Group, Thermo Fisher Scientific)

Moved to industry from a University lectureship in Biochemistry, University of Newcastle upon Tyne, following 7 years’ experience in academia. Now with over 35 years’ experience with Thermo Fisher Scientific using a wide range of analytical equipment and software. Publications range from metabolomics, proteomics to large biopharmaceutical drug analysis. Current job title is the European manager for the BioPharma expert support group. This involves the support of Bio-Pharmaceutical applications to characterise protein and oligonucleotide based bio-therapeutics. This involves ongoing collaborations with the Biopharmaceutical industry and academia. Characterization methods of Bio-therapeutics include, monoclonal antibodies, peptides, AAV analytical development, small and large RNA analysis including sequence mapping of mRNA by LC/HRMS.